Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Palisade Bio, Inc. (PALI : NSDQ)
 
 • Company Description   
Palisade Bio Inc. is a late-stage biopharma company advancing therapies which help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio Inc., formerly known as Seneca Biopharma Inc., is based in CARLSBAD, Calif.

Number of Employees: 13

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.52 Daily Weekly Monthly
20 Day Moving Average: 361,523 shares
Shares Outstanding: 21.88 (millions)
Market Capitalization: $11.38 (millions)
Beta: 1.63
52 Week High: $4.57
52 Week Low: $0.40
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -42.11% -36.61%
12 Week -43.48% -36.48%
Year To Date -60.00% -51.13%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
5800 Armada Drive Suite 210
-
Carlsbad,CA 92008
USA
ph: 858-704-4900
fax: -
ir@palisadebio.com http://www.palisadebio.com
 
 • General Corporate Information   
Officers
Thomas M. Hallam - Chief Executive Officer and Director
James R. Neal - Chairman
J.D. Finley - Chief Financial Officer
Cristina Csimma - Director
Stephanie Diaz - Director

Peer Information
Palisade Bio, Inc. (CORR.)
Palisade Bio, Inc. (RSPI)
Palisade Bio, Inc. (CGXP)
Palisade Bio, Inc. (BGEN)
Palisade Bio, Inc. (GTBP)
Palisade Bio, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 696389105
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/23/22
Share - Related Items
Shares Outstanding: 21.88
Most Recent Split Date: 4.00 (0.17:1)
Beta: 1.63
Market Capitalization: $11.38 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.57 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/23/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.98
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -135.14%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -2,145.95
12/31/21 - -1,479.63
09/30/21 - -
ROA
03/31/22 - -273.04
12/31/21 - -268.78
09/30/21 - -378.80
Current Ratio
03/31/22 - 4.43
12/31/21 - 4.96
09/30/21 - 5.51
Quick Ratio
03/31/22 - 4.43
12/31/21 - 4.96
09/30/21 - 5.51
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -891,833.38
Book Value
03/31/22 - 0.26
12/31/21 - 0.52
09/30/21 - 0.30
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©